Discover the groundbreaking insights on how GSTP1, RASSF1, and RASSF2 methylation in serum can revolutionize the diagnosis of prostate cancer, offering new hope for early detection and personalized treatment strategies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients.
Aykanli et al., Urol J 2024
<!– DOI: 10.22037/uj.v20i.8014 //–>
https://doi.org/10.22037/uj.v20i.8014
This study explores the potential of a liquid biopsy diagnostic panel for prostate cancer, focusing on the hypermethylation status of GSTP1 and RASSF1:RASSF2 genes in cell-free DNA (cfDNA) from plasma samples. The research involved 39 patients undergoing transrectal ultrasound (TRUS)-biopsy and 15 healthy volunteers. The findings revealed that RASSF2 methylation had the highest sensitivity (69%), specificity (39%), and negative predictive value (NPV) (80%) for detecting prostate cancer. The combination of GSTP1 and RASSF1 methylation showed improved diagnostic metrics, with a sensitivity of 46%, specificity of 76%, and NPV of 82%. However, when all three genes’ methylation was considered, sensitivity dropped to 8%, albeit with increased specificity (83%). The study indicates that RASSF2 methylation is more prevalent in prostate cancer patients, suggesting its potential as a diagnostic marker. However, the results also highlight the need for further randomized controlled studies to validate these findings.
Importance: This research contributes to the ongoing search for more accurate diagnostic markers for prostate cancer, addressing the limitations of current PSA measurement methods.